Bayer’s embattled CEO faces growing shareholder opposition
Bloomberg Bayer AG is facing mounting opposition ahead of what’s shaping up to be its most contentious annual meeting in years, with influential shareholders faulting management for failing to foresee the risks of the company’s biggest deal ever. A growing number of shareholders have said they won’t support executives and supervisory board members in a no-confidence vote at Friday’s annual ...
Read More »